Mitochondrial dysfunction promotes microbial composition that negatively impacts on ulcerative colitis development

Ainize Peña-Cearra1,2,3, Deguang Song4, Janire Castelo1

  • 1CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Science and Technology Park Bld 801 A, 48160, Derio, Spain.

PubMed

Insights

Gut microbiota alterations in mice lacking the mitochondrial protein MCJ increase susceptibility to inflammatory bowel disease (IBD). Fecal microbiota transplantation (FMT) reversed this susceptibility, highlighting microbial roles in IBD pathogenesis.

Area of Science:

  • Mitochondrial biology
  • Gut microbiome research
  • Inflammatory Bowel Disease (IBD) pathogenesis

Background:

  • Mitochondrial dysfunction is linked to IBD.
  • MCJ-deficient mice show increased susceptibility to DSS colitis.
  • The role of gut microbiota versus MCJ-deficiency in this phenotype is unclear.

Purpose of the Study:

  • To investigate the role of gut microbiota in MCJ-deficiency-associated colitis.
  • To explore the impact of MCJ deficiency on protein expression pathways.
  • To identify microbial signatures and IgA coating in MCJ-deficient mice.

Main Methods:

  • Fecal microbiota transplantation (FMT) into germ-free mice.
  • Cohousing experiments to alter microbiota composition.
  • Magnetic activated cell sorting (MACS) and 16S rRNA gene sequencing for IgA-SEQ.
  • Analysis of protein expression pathways.

Main Results:

  • FMT from MCJ-deficient mice conferred colitis susceptibility to germ-free recipients.
  • MCJ deficiency impacts protein expression pathways relevant to IBD.
  • High IgA coating of fecal bacteria was observed in MCJ-deficient mice and correlated with disease progression.
  • Microbial signatures associated with complex I deficiency and disease progression were identified.

Conclusions:

  • Gut microbiota dysbiosis plays a critical role in MCJ-deficiency-driven IBD susceptibility.
  • MCJ deficiency affects host-microbe interactions, including IgA coating.
  • Identifying microbial biomarkers could aid in stratifying ulcerative colitis (UC) patients.

Related Concept Videos

Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
199
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
464
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
295
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
156
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
443
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
341